

參考文獻

- [1] 肖崇厚：中藥化學，上海科學技術出版社，pp.141，1985。
- [2] 國家中醫藥管理局中華本草編委會：中華本草 2，上海科學技術出版社，pp708-20，1999。
- [3] 肖培根：新編中藥誌 第一卷，化學工業出版社，pp66-76，2002。
- [4] 徐珞珊、徐國鈞、金蓉鸞、何宏賢：中國藥材學(上)，中國醫藥科技出版社，pp130-5，1996。
- [5] Wang HH. Chung JG. Ho CC. Wu LT. Chang SH. Aloe-emodin effects on arylamine N-acetyltransferase activity in the bacterium *Helicobacter pylori*. *Planta Medica*. 64(2):176-8, 1998.
- [6] Chung JG. Wang HH. Wu LT. Chang SS. Chang WC. Inhibitory actions of emodin on arylamine N-acetyltransferase activity in strains of *Helicobacter pylori* from peptic ulcer patients. *Food & Chemical Toxicology*. 35(10-11):1001-7, 1997.
- [7] Wang HH. Chung JG. Emodin-induced inhibition of growth and DNA damage in the *Helicobacter pylori*. *Current Microbiology*. 35(5):262-6, 1997 .
- [8] Chung JG. Tsou MF. Wang HH. Lo HH. Hsieh SE. Yen YS. Wu LT. Chang SH. Ho CC. Hung CF. Rhein affects arylamine N-acetyltransferase activity in *Helicobacter pylori* from peptic ulcer patients. *Journal of Applied Toxicology*. 18(2):117-23, 1998 .
- [9] Zhu J. Liu Z. Li Y. Inhibition of glucose transporter 1 overexpression in mesangial cells by rhein. [Chinese] *Chung-Hua*

- Nei Ko Tsa Chih Chinese Journal of Internal Medicine.*  
40(8):537-42, 2001.
- [10] Zhang J. Liu Z. Chen Z. Li Y. Li L. Effect of rhein on glucose transporter-1 expression and its function in glomerular mesangial cells. *Chinese Medical Journal.* 112(12):1077-9, 1999.
- [11] Liu Z. Li Y. Zhang J. Modulatory effect of transforming growth factor-beta and Rhein on glucose transporter-1 in human glomerular mesangial cells. [Chinese] *Chung-Hua i Hsueh Tsa Chih* [Chinese Medical Journal]. 79(10):780-3, 1999.
- [12] Menkes CJ. Borderie D. Hernvann A. Ekindjian O. [Inhibition by rhein of nitrosothiol production of human chondrocytes from osteoarthritis in culture]. [French] *Bulletin de l'Academie Nationale de Medecine.* 183(4):785-95; discussion 795-6, 1999.
- [13] Yaron M. Shirazi I. Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. *Osteoarthritis & Cartilage.*7(3):272-80, 1999.
- [14] Pelletier JP. Mineau F. Fernandes JC. Duval N. Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. *Journal of Rheumatology.* 25(12):2417-24, 1998.
- [15] Martel-Pelletier J. Mineau F. Jolicoeur FC. Cloutier JM. Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. *Journal of Rheumatology.* 25(4):753-62, 1998.

- [16] Brun PH. Effect of diacetylrhein on the development of experimental osteoarthritis. A biochemical investigation. *Osteoarthritis & Cartilage*. 5(4):289-91, 1997.
- [17] Carney SL. Effect of diacetyl rhein on the development of experimental osteoarthritis. A biochemical investigation. *Osteoarthritis & Cartilage*. 4(4):251-61, 1996.
- [18] Matsuda H. Shimoda H. Morikawa T. Yoshikawa M. Phytoestrogens from the roots of *Polygonum cuspidatum* (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. *Bioorganic & Medicinal Chemistry Letters*. 11(14):1839-42, 2001.
- [19] Usui T. Ikeda Y. Tagami T. Matsuda K. Moriyama K. Yamada K. Kuzuya H. Kohno S. Shimatsu A. The phytochemical lindleyin, isolated from *Rhei rhizoma*, mediates hormonal effects through estrogen receptors. *Journal of Endocrinology*. 175(2) : 289-96, 2002.
- [20] Sato M. Maulik G. Bagchi D. Das DK. Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. *Free Radical Research*. 32(2):135-44, 2000.
- [21] Maity TK. Mandal SC. Bhakta T. Pal M. Saha BP. Metabolism of 1,8-dihydroxy 3-hydroxy methyl anthraquinone (aloe-emodin) isolated from the leaves of *Cassia tora* in albino rats. *Phytotherapy Research*. 15(5):459-60, 2001.
- [22] Mueller SO. Stopper H. Dekant W. Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450

參考文獻

- enzymes. Bioactivation to genotoxic metabolites. *Drug Metabolism & Disposition*. 26(6):540-6, 1998.
- [23] Liang JW. Hsiu SL. Wu PP. Chao PD. Emodin pharmacokinetics in rabbits. *Planta Medica*. 61(5):406-8, 1995.
- [24] Nicolas P. Tod M. Padoin C. Petitjean O. Clinical pharmacokinetics of diacerein. [Review] [34 refs] *Clinical Pharmacokinetics*. 35(5):347-59, 1998.
- [25] Dahms M. Lotz R. Lang W. Renner U. Bayer E. Spahn-Langguth H. Elucidation of phase I and phase II metabolic pathways of rhein: species differences and their potential relevance. *Drug Metabolism & Disposition*. 25(4):442-52, 1997.
- [26] de Witte P. Metabolism and pharmacokinetics of anthranoids. [Review] [42 refs] *Pharmacology*. 47 Suppl 1:86-97, 1993.
- [27] Krumbiegel G. Schulz HU. Rhein and aloe-emodin kinetics from senna laxatives in man. *Pharmacology*. 47 Suppl 1:120-4, 1993.
- [28] Lemli J. Lemmens L. Metabolism of sennosides and rhein in the rat. *Pharmacology*. 20 Suppl 1:50-7, 1980.
- [29] Moreau JP. Moreau S. Skinner S. Comparative physiological disposition of some anthraquinone glycosides and aglycones. *Biopharmaceutics & Drug Disposition*. 6(3):325-34, 1985.
- [30] Uchino K. Yamamura Y. Saitoh Y. Nakagawa F. Determination of rhein and its conjugates in urine by high-performance liquid chromatography. *Journal of Chromatography. A.* 380(2):462-7, 1986.
- [31] De Witte P. Lemli J. Excretion and distribution of [<sup>14</sup>C]rhein and [<sup>14</sup>C]rhein anthrone in rat. *Journal of Pharmacy & Pharmacology*.

- 40(9):652-5, 1988.
- [32] Cameron BD. Phillips MW. Fenerty CA. Milk transfer of rhein in the rhesus monkey. *Pharmacology*. 36 Suppl 1:221-5, 1988.
- [33] Faber P. Strenge-Hesse A. Relevance of rhein excretion into breast milk. *Pharmacology*. 36 Suppl 1:212-20, 1988.
- [34] Lang W. Pharmacokinetics of <sup>14</sup>C-labelled rhein in rats. *Pharmacology*. 36 Suppl 1:158-71, 1988.
- [35] de Witte P. Lemli J. Metabolism of <sup>14</sup>C-rhein and <sup>14</sup>C-rhein anthrone in rats. *Pharmacology*. 36 Suppl 1:152-7, 1988.
- [36] Sund RB. Elvegard SO. Anthraquinone laxatives: metabolism and transport of danthron and rhein in the rat small and large intestine in vitro. *Pharmacology*. 36 Suppl 1:144-51, 1988.
- [37] Lee JH, Kim JM, Kim C. Pharmacokinetic analysis of rhein in *Rheum undulatum* L. *Journal of Ethnopharmacology*. 84 : 5-9,2003
- [38] Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. *Advan Drug Delivery Rev*. 27 : 201-214,1997.
- [39] Foxwell BM, Mackie A, Ling V and Ryffel B, Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. *Molecular Pharmacology*. 36(4): 543-546, 1989.
- [40] Saeki T, Ueda K, Tanigawara Y, Hori R, and Komano T, Human P-glycoprotein transports cyclosporin A and FK506. *The Journal of Biological Chemistry*. 268 (9): 6077-6080, 1993.
- [41] van Gorkom BA. Timmer-Bosscha H. de Jong S. van der Kolk DM. Kleibeuker JH. de Vries EG. Cytotoxicity of rhein, the active

參考文獻

- metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1. *British Journal of Cancer*. 86(9):1494-500, 2002.
- [42] Wang HW. Chen TL. Yang PC. Ueng TH. Induction of cytochromes P450 1A1 and 1B1 by emodin in human lung adenocarcinoma cell line CL5. *Drug Metabolism & Disposition*. 29(9):1229-35, 2001.
- [43] Sun M. Sakakibara H. Ashida H. Danno G. Kanazawa K. Cytochrome P4501A1-inhibitory action of antimutagenic anthraquinones in medicinal plants and the structure-activity relationship. *Bioscience, Biotechnology & Biochemistry*. 64(7):1373-8, 2000.
- [44] 顏坤熒：原色生藥學，台北南天書局，pp210-12，1996。
- [45] 焦東海、杜上鑒：大黃研究，上海科學技術出版社，pp.94-8, 136-7,144-7, 2000。
- [46] 鄭虎占、董澤宏、余靖：中藥現代研究與應用 第一卷，北京學苑出版社，pp.，1996。
- [47] Budavari S. *The Merck Index*, Merck & Co. Inc., 13<sup>th</sup> ed., NJ, USA. 2001; p. 56
- [48] Agarwal SK, Singh SS, Verma S, Kumar S. Antifungal activity of anthraquinone derivatives from *Rheum emodi*. *Journal of Ethnopharmacology*. 72: 43-6, 2000.
- [49] Shi YQ, Fukai T, Sakagami H, Kuroda J, Miyaoka R, Tamura M,

- Yoshida N, Nomura T. Cytotoxic and DNA damage-inducing activities of low molecular weight phenols from rhubarb. *Anticancer Research*. 21: 2847-53, 2001.
- [50] Kuo PL, Lin TC, Lin CC. The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. *Life Sciences*. 71: 1879-92, 2002.
- [51] Pecere T, Gazzola MV, Mucignat C, Parolin C, Vecchia FD, Cavaggioni A, Basso G, Diaspro A, Salvato B, Carli M, Palu G. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. *Cancer Research*. 60: 2800-4, 2000.
- [52] Saleem R, Faizi S, Siddiqui BS, Ahmed M, Hussain SA, Qazi A, Dar A, Ahmad SI, Qazi MH, Akhtar S, Hasnain SN. Hypotensive effect of chemical constituents from Aloe barbadensis. *Planta Medica*. 67: 757-60, 2001.
- [53] Yagi T, Yamauchi K. Synergistic effects of anthraquinones on the purgative activity of rhein anthrone in mice. *Journal of Pharmacy & Pharmacology*. 51: 93-5, 1999.
- [54] Budavari S. *The Merck Index*, Merck & Co. Inc., 13<sup>th</sup> ed., NJ, USA. p. 1466, 2001.
- [55] Budavari S. *The Merck Index*, Merck & Co. Inc., 13<sup>th</sup> ed., NJ, USA. pp. 629-30, 2001.

參考文獻

- [56] Zhang C, Teng L, Shi Y, Jin J, Xue Y, Shang K, Gu J. Effect of emodin on proliferation and differentiation of 3T3-L1 preadipocyte and FAS activity. *Chinese Medical Journal*. 115: 1035-8, 2002.
- [57] Yim H, Lee YH, Lee CH, Lee SK. Emodin, an anthraquinone derivative isolated from the rhizomes of *Rheum palmatum*, selectively inhibits the activity of casein kinase II as a competitive inhibitor. *Planta Medica*. 65: 9-13, 1999.
- [58] Goel RK, Das Gupta G, Ram SN, Pandey VB. Antiulcerogenic and anti-inflammatory effects of emodin, isolated from *Rhamnus triquerta wall*. *Indian Journal of Experimental Biology*. 29: 230-2, 1991.
- [59] Kuo YC, Sun CM, Ou JC, Tsai WJ. A tumor cell growth inhibitor from *Polygonum hypoleucum Ohwi*. *Life Sciences*. 61: 2335-44, 1997.
- [60] Koyama M, Takahashi K, Chou TC, Darzynkiewicz Z, Kapuscinski J, Kelly TR, Watanabe KA. Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. *Journal of Medicinal Chemistry*. 32: 1594-9, 1989.
- [61] Ishii Y, Tanizawa H, Takino Y. Studies of aloe III. Mechanism of Cathartic effect (2). *Chemical & Pharmaceutical Bulletin*. 38: 197-200, 1990.
- [62] Chang CH, Lin CC, Yang JJ, Namba T, Hattori M.



- Anti-inflammatory effects of emodin from ventilago leiocarpa.  
*American Journal of Chinese Medicine*. 24: 139-42, 1996.
- [63] Lin CC, Chang CH, Yang JJ, Namba T, Hattori M.  
Hepatoprotective effects of emodin from Ventilago leiocarpa.  
*Journal of Ethnopharmacology*. 52: 107-11, 1996.
- [64] Zhan Y. Li D. Wei H. Effect of emodin on development of hepatic fibrosis in rats. [Chinese] *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi*. 20(4):276-8, 2000.
- [65] Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML, Chu SH.  
Immunosuppressive effect of emodin, a free radical generator.  
*European Journal of Pharmacology*. 211: 359-64, 1992.
- [66] Huang HC, Lee CR, Chao PD, Chen CC, Chu SH. Vasorelaxant effect of emodin, an anthraquinone from a Chinese herb. *European Journal of Pharmacology*. 205: 289-94, 1991.
- [67] Chen XY. Effects of emodin and other antibiotics on the antibiotics resistant plasmids of Staphylococcus aureus. *Journal of Nanjing College of Pharmacy*. 16: 48-52, 1985.
- [68] Budavari S. *The Merck Index*, Merck & Co. Inc., 13<sup>th</sup> ed., NJ, USA. p. 391, 2001.
- [69] Choi JS, Lee HJ, Park KY, Ha JO, Kang SS. In vitro antimutagenic effects of anthraquinone aglycones and naphthopyrone glycosides from Cassia tora. *Planta Medica*. 63: 11-4, 1997.
- [70] Semple SJ. Pyke SM. Reynolds GD. Flower RL. In vitro antiviral

參考文獻

- activity of the anthraquinone chrysophanic acid against poliovirus. *Antiviral Research*. 49(3):169-78, 2001.
- [71] Dennis J, Cada. *Drug Facts and Comparisons*, USA. pp. 3777-87, 1999.
- [72] Gerald K, McEvoy. *AHFS Drug Information*, USA. pp. 3374-89, 2000.
- [73] Wachter VJ, Wu CY, and Benet LJ, Overlapping substrate specification and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implication for drug delivery and activity in cancer chemotherapy. *Mol Carcinogen*. 13: 129-134, 1995.
- [74] Mehdi B. *Pharmacokinetics Principles and Applications*. McGRAW-Hill Medical Publishing Division, N.Y, USA, 58-9, 2002.
- [75] 國家藥典委員會：中華人民共和國藥典，化學工業出版社，pp.18-9，附錄 24-5，2000。
- [76] 賴榮祥：原色生藥學，創譯出版社，pp205-7，1976。
- [77] Lin JH, Chiba M, and Baillie TA, Is the role of the small intestine in first-pass metabolism overemphasized? *Pharmacological Reviews*. 51 (2): 135-157, 1999.